# Senescent cells and p16 after chemotherapy

Source: https://onco.cc/technologies/rejuv-age-senescent-cells-after-treatment/  
OnCo record `rejuv-age-senescent-cells-after-treatment` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chemotherapy pushes cells into senescence: they stop dividing but stay alive and keep releasing inflammatory signals. The usual marker, p16INK4a in blood T cells, rises sharply during treatment and is still raised a year later. In one study the rise matched about fifteen years of ordinary ageing, in another the gap in survivors was larger still.

## Summary

p16INK4a expression in peripheral blood T lymphocytes rises with chronological age and is used as a measure of senescent-cell burden. In 33 women with stage I to III breast cancer sampled before anthracycline chemotherapy, immediately after, and at three and twelve months, the median rise in log2 p16INK4a was 0.81 (interquartile range 0.28 to 1.62), a 75 per cent absolute increase, which the authors state is equivalent to the increase seen over 14.7 years of chronological ageing. ARF rose comparably. Expression remained elevated twelve months after treatment ended, so this is not a transient effect of being unwell.

In a separate cohort of 60 young adult survivors of childhood, adolescent and young adult cancer compared with 29 age-matched controls at a median age of 21 years, p16INK4a was 9.6 against 8.9 log2 units (P = 0.005), which the authors describe as a 25-year age acceleration. Nine of those survivors met the criteria for frailty, and their p16INK4a was 10.5 against 9.5 log2 units in robust survivors (P = 0.055), described as a 35-year acceleration. Nine newly diagnosed children sampled before and after therapy rose from 7.3 to 8.9 log2 units (P = 0.002).

The measurements are consistent in direction and large in size. They are also small studies using one marker in one tissue, the reported age equivalents are extrapolations from a cross-sectional age curve rather than observed ageing, and no trial has shown that lowering p16INK4a changes a person's health. That gap is the reason senolytics are being tested and the reason they cannot yet be recommended.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; biological-ageing; senescence; biomarker
- Principle: Genotoxic chemotherapy activates the p16INK4a/RB and p53/p21 arrest programmes. Arrested cells persist and secrete the senescence-associated secretory phenotype, a mixture of interleukins, chemokines and matrix metalloproteinases that drives local inflammation and, in animal models, several features of ageing.
- Strengths: Prospective before-and-after sampling in the same people; Effect persists at twelve months rather than resolving with recovery; Replicated in an independent survivor cohort and in newly diagnosed children
- Limitations: Small samples, one marker, one tissue; The age equivalents are extrapolations from a cross-sectional curve; No evidence that lowering the marker changes any outcome

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cellular_senescence
- Sanoff et al., Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer (JNCI 2014): https://doi.org/10.1093/jnci/dju057
- Smitherman et al., Accelerated aging among childhood, adolescent and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty (Cancer 2020): https://doi.org/10.1002/cncr.33112

## Connected records

- technologies: [Epigenetic age after cancer treatment](https://onco.cc/technologies/rejuv-age-epigenetic-clocks/), [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- pathways: [Cellular senescence](https://onco.cc/pathways/senescence/)
- terms: [Hallmark (2022): senescent cells](https://onco.cc/terms/senescent-cells/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-age-senescent-cells-after-treatment.json